Sign in
Taking people in United StatesEarly phase 1

Testing an SGLT2 inhibitor to lower high insulin levels in type 1 diabetes

Tests an SGLT2 inhibitor to lower insulin needs in adults with type 1 diabetes.

Key facts

Who runs it
Vanderbilt University Medical Center
Where
Nashville, United StatesSee the site
Trial code
Registry title
Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes
Status
Recruiting
Phase
Early phase 1
People taking part
27 people, planned
Started
3 Jul 2025
Expected to end
Dec 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Study Visit 1
  • Placebo
  • Study Visit 2
  • Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
Record updated
23 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 1 diabetes, adults with GCK-MODY, and adults without diabetes. It tests whether lowering insulin needs helps heart and blood sugar health.

Age
18 to 60 years
Sex
All sexes
Disease stage
Type 1 diabetes for 1 to 30 years with HbA1c 5.7-7.5% (39–58 mmol/mol), or GCK-MODY with HbA1c 5.7-7.5% (39–58 mmol/mol), or no diabetes with HbA1c less than 5.5% (37 mmol/mol). Body mass index 18-28 kg/m² and weight of at least 50 kg (110 lb).
Earlier treatment
People with type 1 diabetes must use automated insulin delivery and no diabetes medicine other than insulin.
Biomarker or test result
GCK-MODY participants need a positive GCK gene test. People with type 1 diabetes need fasting C-peptide of 0.7 ng/mL or less.

Main reasons for not taking part

  • Severe low blood sugar in the past 3 months
  • Hospital stay for diabetic ketoacidosis in the past 6 months
  • Pregnancy, or being peri- or post-menopausal
  • Active smoker
  • Kidney or liver problems, or certain medicines such as steroids, thiazide diuretics or blood pressure medicines

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • Age: 18-60 years BMI: 18-28 kg/m² Weight: ≥ 50 kg
  • T1DM Participants:
  • Duration of T1DM: 1-30 years HbA1c: 5.7-7.5% Insulin Therapy: Using automated insulin delivery
  • GCK-MODY Participants:
  • HbA1c: 5.7-7.5% Genetic Confirmation: Positive GCK sequencing
  • Control Participants:
  • HbA1c: less than 5.5%
  • ** Exclusion Criteria: Severe Hypoglycemia: ≥1 episode in the past 3 months
  • Comorbidities:
  • Any hospital admissions for diabetic ketoacidosis in the past 6 months
  • SBP greater than 140 mmHg and DBP greater than 100 mmHg
  • eGFR by MDRD equation of less than 60 mL/min/1.73 m²
  • AST or ALT greater than 2.5 times ULN
  • Hct less than 35%; Medications:
  • Any antioxidant vitamin supplement within 2 weeks before the study
  • Any systemic glucocorticoid
  • Antipsychotics
  • Atenolol, Metoprolol, Propranolol
  • Niacin
  • Any thiazide diuretic
  • Any oral contraceptive pill with greater than 35 mcg ethinyl estradiol
  • Growth hormone
  • Any immunosuppressant
  • Antihypertensive
  • Any antihyperlipidemic; Other:
  • Pregnancy
  • Tanner stage less than 5
  • Peri- or post-menopausal women
  • Active smoker; T1DM Participants:; Medications: Any diabetes medication except insulin C-peptide: greater than 0.7 ng/mL (fasting); GCK-MODY Participants:; None specific

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 60 years old?

Where in United States

  • Vanderbilt University Medical CenterNashville, United StatesContact: Daniel J Moore, MD, PhDTaking people

About the trial

What the trial wants to find out

This study aims to understand the heart and blood sugar health benefits of using an adjunctive therapy to lower high insulin levels in people with type 1 diabetes. The investigators will also look at people with a specific type of diabetes called Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY) and those without diabetes to help interpret the results. The investigators will use a medication that helps the body get rid of sugar, called and SGLT2 inhibitor, with the goal to reduce the body's insulin requirements. The investigators believe this could lead to better heart and blood sugar health, including a better response to insulin and more available nitric oxide, a gas that helps blood vessels function well. The investigators will compare heart and blood sugar health risk factors in participants with type 1 diabetes, participants with Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY), and non-diabetic healthy volunteers under two conditions: high insulin levels typical of type 1 diabetes and normal insulin levels typical of the other two groups.

The 2 groups in the trial

  • High insulinTreatment being tested

    Participants will receive a "high insulin infusion" (Hi-Ins) prior to quantifying insulin resistance and endothelial function. This infusion will result in participants having insulin levels similar to patients with type 1 diabetes for five hours.

    Treatment: Study Visit 1, Placebo, and Study Visit 2

  • Normal insulinExisting treatment, for comparison

    Participants will receive a "normal insulin infusion" (Eu-Ins) prior to quantifying insulin resistance and endothelial function. This infusion will result in participants having insulin levels similar to people without diabetes and people with GCK-MODY for five hours.

    Treatment: Study Visit 1, Placebo, Study Visit 2, and Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes
Plain-language title
Testing an SGLT2 inhibitor to lower high insulin levels in type 1 diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06609356, who can take part
Record updated
23 December 2025